stockrowPfizer Inc.
PFE Healthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.
- Revenue
- −0.43%
- EPS
- −7.98%
- Free cash flow
- +20.0%
- Total debt
- +1.55%
Quarter to September 2026, against a year earlier
Follow PFE
Alert me
Pfizer Inc. (PFE) Total debt
Pfizer Inc.'s total debt at the end of fiscal 2025 was $64.8B, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $62.7B. Over the past ten years it has ranged from $35.8B (fiscal 2022) to $71.9B (fiscal 2023); the current reading is higher than 91% of that period. Pfizer Inc. ranks 2nd of 21 Drug Manufacturers General companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $64.8B | 0.69% |
| FY2024 | $64.4B | (10.48%) |
| FY2023 | $71.9B | 100.64% |
| FY2022 | $35.8B | (6.78%) |
| FY2021 | $38.4B | (3.51%) |
| FY2020 | $39.8B | (23.61%) |
| FY2019 | $52.2B | 24.94% |
| FY2018 | $41.7B | (4.03%) |
| FY2017 | $43.5B | 3.34% |
| FY2016 | $42.1B | 8.19% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $62.7B | (0.83%) |
| Jun 2026 | $63.2B | (1.96%) |
| Mar 2026 | $64.5B | (0.52%) |
| Dec 2025 | $64.8B | 5.00% |
| 43 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| PFE Pfizer Inc. | $62.7B |
| AMGN Amgen Inc. compare | $54.0B |
| NVS Novartis AG compare | $46.3B |
| BMY Bristol Myers Squibb Company compare | $42.9B |
| GSK GSK PLC Sponsored ADR compare | $31.9B |
| AZN AstraZeneca PLC compare | $31.4B |
| GILD Gilead Sciences, Inc. compare | $26.2B |
| NVO Novo Nordisk A/S compare | $21.8B |
| SNY Sanofi compare | $20.7B |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on PFE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement